NEURON23

neuron23-logo

Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. The company was founded in 2018 and is based in San Francisco, California, United States.

#People #Financial #Event #Website #More

NEURON23

Industry:
Health Care Medical Pharmaceutical

Founded:
2018-01-01

Address:
San Francisco, California, United States

Country:
United States

Website Url:
http://www.neuron23.com

Total Employee:
11+

Status:
Active

Total Funding:
213.5 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress



Current Advisors List

beth-seidenberg_image

Beth Seidenberg Board Member @ Neuron23
Board_member
2020-12-01

not_available_image

Amrit Nagpal Board Member @ Neuron23
Board_member
2020-12-01

not_available_image

Michael Almstetter Board Member @ Neuron23
Board_member
2020-12-01

jim-scopa_image

Jim Scopa Board Of Director, Chair of Audit Committee @ Neuron23
Board_member
2022-03-30

valentin-barsan_image

Valentin Barsan Board of Director @ Neuron23
Board_member
2022-03-30

kevin-raidy_image

Kevin Raidy Board Member @ Neuron23
Board_member
2020-12-01

Current Employees Featured

sam-jackson_image

Sam Jackson
Sam Jackson Chief Medical Officer @ Neuron23
Chief Medical Officer
2022-04-01

nancy-stagliano_image

Nancy Stagliano
Nancy Stagliano Chief Executive Office @ Neuron23
Chief Executive Office
2020-10-01

adam-knight_image

Adam Knight
Adam Knight Founder & Chief Business Officer @ Neuron23
Founder & Chief Business Officer

Founder


adam-knight_image

Adam Knight

Investors List

surveyor-capital_image

Surveyor Capital

Surveyor Capital investment in Series C - Neuron23

cowen-healthcare-investments_image

Cowen Healthcare Investments

Cowen Healthcare Investments investment in Series C - Neuron23

acorn-bioventures_image

Acorn Bioventures

Acorn Bioventures investment in Series C - Neuron23

westlake-village-biopartners_image

Westlake Village BioPartners

Westlake Village BioPartners investment in Series C - Neuron23

softbank-vision-fund_image

SoftBank Vision Fund

SoftBank Vision Fund investment in Series C - Neuron23

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series C - Neuron23

redmile-group_image

Redmile Group

Redmile Group investment in Series C - Neuron23

hbm-partners_image

HBM Partners

HBM Partners investment in Series C - Neuron23

kleiner-perkins-caufield-byers_image

Kleiner Perkins

Kleiner Perkins investment in Series C - Neuron23

hbm-healthcare-investments-ag_image

HBM Healthcare Investments AG

HBM Healthcare Investments AG investment in Series C - Neuron23

Key Employee Changes

Date New article
2022-04-12 Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer

Official Site Inspections

http://www.neuron23.com Semrush global rank: 5.5 M Semrush visits lastest month: 1.55 K

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Neuron23"

Neuron23 - LinkedIn

Neuron23โ„ข Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.See details»

Neuron23 - Crunchbase Company Profile & Funding

Organization. Neuron23 . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Neuron23 is a developer โ€ฆSee details»

Neuron23, Inc. - Drug pipelines, Patents, Clinical trials

May 22, 2025 "Neuron23 is pioneering an entirely new approach to treating genetically defined neurological and immunological diseases and I am thrilled to join the organization at such a pivotal time in its development," said Mr. Yost. โ€ฆSee details»

Neuron23 - Work in biotech

Neuron23 is a biotech company aiming to develop precision medicine for complex neurological and immunological diseases. They are leveraging recent advancements in human genetics to โ€ฆSee details»

Neuron23, Inc. | HBM Partners

Neuron23, Inc., is an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Founded in partnership with Origenis GmbH, Neuron23 is currently โ€ฆSee details»

Neuron23โ„ข Closes $113.5 Million Series A and B โ€ฆ

Dec 16, 2020 Neuron23โ„ข Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent ...See details»

Neuron23โ„ข Closes $113.5 Million Series A and B Financing

Dec 16, 2020 About Neuron23โ„ข Neuron23โ„ข Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and โ€ฆSee details»

Neuron23 - Leadership Team - The Org

The Leadership Team at Neuron23 drives strategic direction and innovation, collaborating across research, translational development, and drug discovery to advance precision medicine โ€ฆSee details»

Neuron23

Neuron23 was founded in late 2018 with the goal of changing the way drugs were discovered and developed for neurodegenerative and immunological diseases, by leveraging data science to โ€ฆSee details»

Neuron23 - VentureRadar

Similar Companies: Envisagenics USA Privately Held Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. The company's mission is to boost the creation of โ€ฆSee details»

Neuron23, Inc. - HBM Healthcare

Neuron23, Inc., is an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Founded in โ€ฆSee details»

Neuron23, Inc. (Neuron23, Inc.) - ่ฏ็‰ฉ็ฎก็บฟ_ไธ“ๅˆฉ_ไธดๅบŠ่ฏ•้ชŒ_ๆŠ•่ž่ฅ โ€ฆ

May 22, 2025 About Neuron23 Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological โ€ฆSee details»

Neuron23 Announces $96.5 Million Series D Financing and

22 hours ago Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. โ€ฆSee details»

Neuron23 Announces $96.5 Million Series D Financing and First โ€ฆ

23 hours ago Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. โ€ฆSee details»

Neuron23

In addition to her commitment to Neuron23, Nancy serves as chair of the board of a number of biotechnology companies, including Star Therapeutics, Electra Therapeutics and Latigo โ€ฆSee details»

Neuron23 - Contacts, Employees, Board Members, Advisors

Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. โ€ฆSee details»

Neuron23 Announces $96.5 Million Series D Financing and First โ€ฆ

23 hours ago Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinsonโ€™s Disease Business โ€ฆSee details»

Neuron23: Nancy Stagliano, CEO - by Dylan Neel - Biomarker

Jul 21, 2022 In addition to her role at Neuron23, Dr. Stagliano serves as chair of the board of Star Therapeutics, Electra Therapeutics, and Latigo Biosciences. She is active in philanthropy โ€ฆSee details»

Neuron23 doses first subject in trial of NEU-411 for Parkinson's

2 hours ago Neuron23 CEO Nancy Stagliano said: โ€œThe Series D financing represents further endorsement of Neuron23โ€™s industry-leading approach, which leverages state-of-the-art โ€ฆSee details»

Careers - Neuron23

Neuron23 offers a highly competitive total rewards package including a comprehensive set of benefits, generous paid time off, and stock options. Our benefits include: Medical Medical โ€ฆSee details»

linkstock.net © 2022. All rights reserved